FDA Tells Congress it is Mulling Strategies to Regulate DTC Genetic Tests as Medical Devices | GenomeWeb

Originally published July 23.

By Turna Ray

WASHINGTON, DC – At a congressional hearing on direct-to-consumer genomic testing this week, the US Food and Drug Administration stated unequivocally for the first time that it considers the tests marketed by these firms to be medical devices requiring the agency's clearance or approval. Furthermore, a high-ranking FDA official acknowledged that the agency has waited too long to take action against this rapidly growing industry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.